Thanks.
But I’m not sure how you say the FDA is only 20%. I would say that is 100% because it’s been a 100% blocker to date (although on other applications).
But the real problem with your analysis that if everything else is satisfactory, Novartis could sign on and progress the FDA, whatever that means, as well as everything else which needs to be progressing. To accept your position, you have to accept Novartis are happy to have everything held in limbo for 6 months and counting… during a global pandemic where stems are touted to be a miracle cure. I think this is unlikely.
More likely, Novartis didn’t think the clinical data stacks up. Or, it’s just not commercially viable because it’s too expensive and other treatments are racing ahead at warp speed (unlike MSB’s stems).
- Forums
- ASX - By Stock
- MSB
- Growing doubt on COVID-19 Application
Growing doubt on COVID-19 Application, page-56
-
-
- There are more pages in this discussion • 4,679 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online